Company intelligence / Profile preview

Biomeva

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

Biomeva is a leading German biopharmaceutical CMO, offering cGMP manufacturing of microbially produced proteins from clinical to commercial scale using E. coli and yeast systems; since acquisition by AGC Asahi Glass in 2016, activities are focused under the AGC Biologics CDMO group[1][2][3].

Modalities: Recombinant proteinBiologicMicrobial therapy
Industry: Contract Manufacturing Organization

Partnerships

Boehringer Ingelheim (production alliance)[1]

Beyond the preview

Go deeper on Biomeva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomeva.

Explore the full profile